Our results demonstrate the feasibility of expressing a therapeutic protein from multiple fragments deliverable by AAV vectors, which could be relevant to many genetic diseases caused by loss-of-function mutations in extra-large genes, such as nemaline- or RYR1-related myopathies. Here, RYR1 is linked to hereditary disease.